Related references
Note: Only part of the references are listed.Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
William G. Wierda et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia
Tadeusz Robak et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
M. Hallek et al.
LANCET (2010)
Stem Cell Transplantation in Chronic Lymphocytic Leukemia
John G. Gribben
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)
Relevance of the Immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens
Katherine I. Lin et al.
BLOOD (2009)
First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia
Barbara F. Eichhorst et al.
BLOOD (2009)
Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission - long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG)
Carmen D. Schweighofer et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Bendamustine in B-Cell Malignancies: The New 46-Year-Old Kid on the Block
Varsha Gandhi et al.
CLINICAL CANCER RESEARCH (2009)
Phase III Randomized Study of Bendamustine Compared With Chlorambucil in Previously Untreated Patients With Chronic Lymphocytic Leukemia
Wolfgang U. Knauf et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia
Constantine S. Tam et al.
BLOOD (2008)
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia:: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
Michael Hallek et al.
BLOOD (2008)
Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia
Andy C. Rawstron et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
MiR-15a and miR-16-1 cluster functions in human leukemia
George A. Calin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia
Claire Dearden et al.
BLOOD (2008)
Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia
Peter Hillmen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial
D. Catovsky et al.
LANCET (2007)
Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997
Ian W. Flinn et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: Results from the US Intergroup Phase III Trial E2997
Michael R. Grever et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus
P. Dreger et al.
LEUKEMIA (2007)
Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia
William G. Wierda et al.
BLOOD (2007)
Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia
Maria Ilaria Del Principe et al.
BLOOD (2006)
Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia
Giovanni D'Arena et al.
AMERICAN JOURNAL OF HEMATOLOGY (2006)
Clinical implications of ZAP-70 expression in chronic lymphocytic leukemia
Francesc Bosch et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2006)
Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation
Apostolia-Maria Tsimberidou et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia
A Kröber et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia
BF Eichhorst et al.
BLOOD (2006)
Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: Justification for risk-adapted therapy
JC Byrd et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia
JG Gribben et al.
BLOOD (2005)
A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia
GA Calin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia:: Results of a phase II trial
T Elter et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia
W Wierda et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia
MJ Keating et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Immunoglobulin gene segment usage, location and immunogenicity in mutated and unmutated chronic lymphocytic leukaemia
K Mauerer et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011
JC Byrd et al.
BLOOD (2005)
Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions
G Lozanski et al.
BLOOD (2004)
ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia
LZ Rassenti et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias
GA Calin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)
JC Byrd et al.
BLOOD (2003)
Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia
GA Calin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia
N Gupta et al.
LEUKEMIA (2002)
Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy
S Stilgenbauer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study
MJ Keating et al.
BLOOD (2002)
Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma - Implications for clinical trials in this patient population
JG Perkins et al.
CANCER (2002)
Somatically mutated Ig VH3-21 genes characterize a new subset of chronic lymphocytic leukemia
G Tobin et al.
BLOOD (2002)
CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease
TJ Hamblin et al.
BLOOD (2002)
Impact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011
VA Morrison et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Rituximab dose-escalation trial in chronic lymphocytic leukemia
SM O'Brien et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Rituximab using a thrice weekly dosing schedule in B-Cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity
JC Byrd et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia
SM O'Brien et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Genomic aberrations and survival in chronic lymphocytic leukemia.
H Döhner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.
KR Rai et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
